Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

Also called NCT03485092

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03485092
Other papers using this trial's data
  • Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF) Circulation, 2021-02-09 DOI, PubMed 33186500, PMC7864599 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03485092. Randomized; quadruple masking; primary purpose treatment. Start 2018-03-16 (actual); primary completion 2020-03-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects
Acronym
SUGAR-DM-HF
Condition
Heart Failure
Condition
Diabetes Mellitus
Intervention (Drug)
Empagliflozin 10 MG
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
NHS Greater Glasgow and Clyde (class: other)
Collaborator
University of Glasgow (class: other)

Record details

Record id
cardio:ct-nct03485092
Content hash
12549386753f18d01608dbccf4eea278072e4520bf8a60bbcd5c7c7798bd19e5